US FDA advisory committee rejects approval of Novartis' heart failure drug ... pharmabiz.com The US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted against approval of Novartis' RLX030 (serelaxin) for the treatment of acute heart failure (AHF). Data presented at advisory committee meeting ... |
